By Mathym
The objective of the SPCCT project is to develop and validate a widely accessible, new quantitative and analytical in vivo imaging technology combining Spectral Photon Counting CT and contrast agents, to accurately and early detect, characterize and monitor neurovascular and cardiovascular disease. The spectral Photon Counting CT is developed by Philips whereas the imaging probe is based on Mathym's technology. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 668142.
